微生物与感染
2025年1月9日 星期四   首页 |  主编心语 |  期刊介绍 |  编委阵容 |  投稿指南 |  出版道德 |  期刊订阅 |  联系我们 | English
微生物与感染  2019, Vol. 14 Issue (4): 252-258    DOI: 10.3969/j.issn.1673-6184.2019.04.009
  综述 本期目录 | 过刊浏览 | 高级检索 |
抗人类免疫缺陷病毒1型广谱中和抗体的研究进展
张子凌,刘明斌,徐建青,张晓燕
复旦大学附属公共卫生临床中心,上海 201508
Progress on broadly neutralizing antibodies against human immunodeficiency virus type 1
ZHANG Ziling, LIU Mingbin, XU Jianqing, ZHANG Xiaoyan
Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China
全文: PDF (596 KB)   HTML (1642)
输出: BibTeX | EndNote (RIS)      
摘要: 现行抗反转录病毒治疗药物的联合应用可有效抑制艾滋病进程并显著延长患者寿命,但由于人类免疫缺陷病毒1型(human immunodeficiency virus type 1,HIV-1)潜伏库的存在,艾滋病迄今尚无法治愈。近年发现抗HIV广谱中和抗体能有效降低患者体内病毒载量并延缓疾病进程,为研发艾滋病疫苗和治愈策略带来了曙光,尤其是序贯免疫策略的使用极大推进了广谱中和抗体的开发和应用进程。2018年,美国食品药品管理局(Food and Drug Administration,FDA)批准了第1个临床应用的广谱中性单克隆和抗体,无疑为抗HIV单克隆抗体药物的研发注入了一支强心剂。本文围绕近年来抗HIV广谱中和抗体的研究进展进行综述,探讨未来广谱中和抗体研发面临的挑战。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
张子凌
刘明斌
徐建青
张晓燕
关键词 人类免疫缺陷病毒1型广谱中和抗体免疫策略疫苗    
Abstract:The morbidity and mortality caused by human immunodeficiency virus type 1 (HIV)/acquired immunodeficiency syndrome (AIDS) were significantly controlled through the combination of anti-HIV-1 therapy. However, HIV/AIDS still could not be cured because of the persistence of HIV-1 reservoir. The broadly neutralizing antibody (bNAb) can effectively reduce the HIV-1 viral load and slow down disease progress, which might be an effective strategy to control HIV/AIDS. The practice of sequential immune strategies has greatly promoted the development of bNAbs. In March 2018, US Food and Drug Administration (FDA) approved the first monoclonal bNAb for the treatment of adult with multidrug resistant HIV, which greatly inspired the enthusiasm for bNAb development. The present paper reviewed the research progress and challenging on bNAb development in recent years.
Key wordsHuman immunodeficiency virus type 1    Broadly neutralizing antibody    Immunization strategy    Vaccine
基金资助:“十三五”国家科技重大专项(2017ZX10202102)
通讯作者: 张晓燕   
引用本文:   
张子凌,刘明斌,徐建青,张晓燕. 抗人类免疫缺陷病毒1型广谱中和抗体的研究进展[J]. 微生物与感染, 2019, 14(4): 252-258.
ZHANG Ziling, LIU Mingbin, XU Jianqing, ZHANG Xiaoyan. Progress on broadly neutralizing antibodies against human immunodeficiency virus type 1. JOURNAL OF MICROBES AND INFECTIONS, 2019, 14(4): 252-258.
链接本文:  
http://jmi.fudan.edu.cn/CN/10.3969/j.issn.1673-6184.2019.04.009     或     http://jmi.fudan.edu.cn/CN/Y2019/V14/I4/252

版权所有 © 2008 《微生物与感染》编辑部
地址:上海市医学院路138号 邮编:200032
Tel:021-54237633 Fax:021-64434224    E-mail:jmi@fudan.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发  技术支持:support@magtech.com.cn